Market Access Sponsored The pre-commercial case for connecting data before acquiring... For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.
Sales & Marketing AI and pharma launch - Within3’s Jason Smith Jason Smith, CTO of AI and analytics at Within3, discusses data-fuelled agile launches and smarter decision-making.
Market Access Sponsored From first approval to lasting value: What sets successful e... Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.
Market Access The new commercialisation playbook: What BIO 2026 taught eme... BIO International focused on how emerging biotech companies should approach their first product launch outside the United States, typically in Europe.
Market Access Why global pharmaceutical reforms are quietly redirecting ra... Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs
Digital The cliff was never the crisis: Pharma’s strategy problem The patent cliff isn't the problem. It's the symptom.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.